Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
BLA FilingZ-RostudirsenPositive
AI Analysis
Summary
Dyne Therapeutics announced FDA acceptance of a BLA for Z-Rostudirsen in exon 51 DMD with Priority Review granted and a PDUFA target action date of January 21, 2027. This represents a significant regulatory milestone for the investigational treatment.
Outcome Details
BLA accepted with Priority Review granted
Importance:8/10
Sentiment:
0.80
FDABLAPriority ReviewDMDDuchenne Muscular DystrophyRare Disease
Related Companies
Read the original article
Published by GlobeNewswire Clinical Studies on July 20, 2026 11:30 AM